Market Overview

UPDATE: H.C. Wainwright & Co. Initiates Coverage on Seattle Genetics on Good Potential for Adcetris

Share:
Related SGEN
Seattle Genetics Offers Data Supporting Antibody-Drug Conjugate, Novel Immuno-Oncology Programs at AACR Meeting
The Most Notable Insider Buys And Sells Of Last Week
Who's Next After Medivation? (Seeking Alpha)

In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on Seattle Genetics (NASDAQ: SGEN) with a Buy rating and $65.00 price target.

In the report, H.C. Wainwright & Co. noted, “We believe that Adcetris, anti-CD30-targeted antibody drug conjugate (ADC), already approved for the treatment of refractory Hodgkin's lymphoma and anaplastic large cell lymphoma, could show further robust activity allowing it to move into new cancer indications and earlier lines of therapy. While Street expectations for SGEN are high, we also believe there could be attractive upside based on prospects for Adcetris, other ADCs, and the technology platform.”

Seattle Genetics closed on Friday at $51.78.

Latest Ratings for SGEN

DateFirmActionFromTo
Jul 2016BarclaysMaintainsOverweight
Jul 2016Cantor FitzgeraldDowngradesBuyHold
Mar 2016SunTrust Robinson HumphreyInitiates Coverage onNeutral

View More Analyst Ratings for SGEN
View the Latest Analyst Ratings

Posted-In: Andrew S. Fein H.C. Wainwright & Co.Analyst Color Initiation Analyst Ratings

 

Related Articles (SGEN)

View Comments and Join the Discussion!